| Title: |
Overview of the current use of levosimendan in France: a prospective observational cohort study |
| Authors: |
Cholley, Bernard; Bojan, Mirela; Guillon, Benoit; Besnier, Emmanuel; Mattei, Mathieu; Levy, Bruno; Ouattara, Alexandre; Tafer, Nadir; Delmas, Clément; Tonon, David; Rozec, Bertrand; Fellahi, Jean-Luc; Lim, Pascal; Labaste, François; Roubille, François; Caruba, Thibaut; Mauriat, Philippe; Barbot, Olivier; Laurent, Berthomieu; Besselat, Anne-Marie; Katrien, Blanchart; Bougle, Adrien; Bourgoin, Pierre; Arnaud, Causeret; Charbonneau, Hélène; Cristinar, Mircea; Desebbe, Olivier; Eljezi, Veldat; Genet, Thibaud; Grenier, Maxime; Guinot, Pierre Grégoire; Lebel, Stéphane; Levy, Yael; Lion, François; Mansourati, Jacques; Marlière, Stéphanie; Martin, Anne-Céline; Mebazaa, Alexandre; Mohammad, Usman; Monsegu, Jacques; Nesseler, Nicolas; Orsel, Isabelle; Puymirat, Etienne; Recher, Morgan; Soussi, Sabri; Troussard, Vincent; Uhry, Sabrina; Zirphile, Xavier |
| Contributors: |
Hôpital Européen Georges Pompidou APHP (HEGP); Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO); Innovations thérapeutiques en hémostase = Innovative Therapies in Haemostasis (IThEM - U1140); Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité); Hôpital Marie-Lannelongue; Groupe Hospitalier Paris Saint-Joseph (hpsj); Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP); Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon); CHU Rouen; Normandie Université (NU); Endothélium, valvulopathies et insuffisance cardiaque (EnVI); Université de Rouen Normandie (UNIROUEN); Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM); Service de Cardiologie CHRU Nancy; Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy); Service de Réanimation Médicale CHRU Nancy; Biologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases (BMC); Université de Bordeaux (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM); CHU de Bordeaux Pellegrin Bordeaux; REICATRA, Recherche et Enseignement en IC Avancée, Transplantation, Assistance; Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN); Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE); Hôpital de la Timone CHU - APHM (TIMONE); ITX-lab unité de recherche de l'institut du thorax UMR1087 UMR6291 (ITX-lab); Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE); Nantes Université - pôle Santé; Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé; Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ); Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN); Université Claude Bernard Lyon 1 (UCBL); Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE); Institut Mondor de Recherche Biomédicale (IMRB); Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12); Pôle Anesthésie Réanimation CHU de Toulouse; Centre Hospitalier Universitaire de Toulouse (CHU Toulouse); Physiologie & médecine expérimentale du Cœur et des Muscles U 1046 (PhyMedExp); Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM); Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier); Hôpital Haut-Lévêque CHU Bordeaux; Centre Hospitalier Universitaire de Bordeaux (CHU Bordeaux); Université de Bordeaux (UB); Centre Hospitalier Saint Jean de Perpignan (CH Perpignan); CHU Caen Normandie – Centre Hospitalier Universitaire de Caen Normandie (CHU Caen Normandie); Université de Caen Normandie (UNICAEN); Hôpital de la Cavale Blanche - CHRU Brest (CHU - BREST); Optimisation des régulations physiologiques (ORPHY (EA 4324)); Université de Brest (UBO EPE)-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Institut Brestois Santé Agro Matière (IBSAM); Université de Brest (UBO EPE)-Université de Brest (UBO EPE) |
| Source: |
ISSN: 2110-5820 ; Annals of Intensive Care ; https://hal.science/hal-04179341 ; Annals of Intensive Care, 2023, 13 (1), pp.69. ⟨10.1186/s13613-023-01164-3⟩. |
| Publisher Information: |
CCSD; SpringerOpen |
| Publication Year: |
2023 |
| Subject Terms: |
[SDV]Life Sciences [q-bio] |
| Description: |
International audience ; Abstract Background Following the results of randomized controlled trials on levosimendan, French health authorities requested an update of the current use and side-effects of this medication on a national scale. Method The France-LEVO registry was a prospective observational cohort study reflecting the indications, dosing regimens, and side-effects of levosimendan, as well as patient outcomes over a year. Results The patients included ( n = 602) represented 29.6% of the national yearly use of levosimendan in France. They were treated for cardiogenic shock ( n = 250, 41.5%), decompensated heart failure ( n = 127, 21.1%), cardiac surgery-related low cardiac output prophylaxis and/or treatment ( n = 86, 14.3%), and weaning from veno-arterial extracorporeal membrane oxygenation ( n = 82, 13.6%). They received 0.18 ± 0.07 µg/kg/min levosimendan over 26 ± 8 h. An initial bolus was administered in 45 patients (7.5%), 103 (17.1%) received repeated infusions, and 461 (76.6%) received inotropes and or vasoactive agents concomitantly. Hypotension was reported in 218 patients (36.2%), atrial fibrillation in 85 (14.1%), and serious adverse events in 17 (2.8%). 136 patients (22.6%) died in hospital, and 26 (4.3%) during the 90-day follow-up. Conclusions We observed that levosimendan was used in accordance with recent recommendations by French physicians. Hypotension and atrial fibrillation remained the most frequent side-effects, while serious adverse event potentially attributable to levosimendan were infrequent. The results suggest that this medication was safe and potentially associated with some benefit in the population studied. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1186/s13613-023-01164-3 |
| Availability: |
https://hal.science/hal-04179341; https://hal.science/hal-04179341v1/document; https://hal.science/hal-04179341v1/file/2023%20Chollet%20et%20al.,%20Overview%20of.pdf; https://doi.org/10.1186/s13613-023-01164-3 |
| Rights: |
https://about.hal.science/hal-authorisation-v1/ ; info:eu-repo/semantics/OpenAccess |
| Accession Number: |
edsbas.46B01DF7 |
| Database: |
BASE |